Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Jilma

Showing results (131-140 of 138) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 138 results.
Scientific Reports|July 23, 2016
Differential in vivo activation of monocyte subsets during low-grade inflammation through experimental endotoxemia in humansB Thaler, P J Hohensinner, K A Krychtiuk, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 6, 2017
Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trialF Eskandary, B Jilma, J Mühlbacher, et al.
Journal of Thrombosis and Haemostasis : JTH|May 17, 2017
Myeloid but not epithelial tissue factor exerts protective anti-inflammatory effects in acid aspiration-induced acute lung injuryJ B Kral-Pointner, W C Schrottmaier, V Horvath, et al.
The Journal of Infectious Diseases|July 1, 2008
Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccineE Tauber, H Kollaritsch, F von Sonnenburg, et al.
Journal of Thrombosis and Haemostasis : JTH|May 29, 2012
Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasmaM E Gorczyca, S C Nair, B Jilma, et al.
Frontiers in Pharmacology|August 8, 2022
Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)M Karolyi, E Pawelka, S Omid, et al.
Leukemia|August 1, 2017
Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target siteE Hadzijusufovic, K Albrecht-Schgoer, K Huber, et al.
Leukemia|December 3, 2016
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinibL Kazianka, C Drucker, C Skrabs, et al.
Pageof 14

Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
Scientific Reports|July 23, 2016
Differential in vivo activation of monocyte subsets during low-grade inflammation through experimental endotoxemia in humansB Thaler, P J Hohensinner, K A Krychtiuk, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 6, 2017
Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trialF Eskandary, B Jilma, J Mühlbacher, et al.
Journal of Thrombosis and Haemostasis : JTH|May 17, 2017
Myeloid but not epithelial tissue factor exerts protective anti-inflammatory effects in acid aspiration-induced acute lung injuryJ B Kral-Pointner, W C Schrottmaier, V Horvath, et al.
The Journal of Infectious Diseases|July 1, 2008
Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccineE Tauber, H Kollaritsch, F von Sonnenburg, et al.
Journal of Thrombosis and Haemostasis : JTH|May 29, 2012
Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasmaM E Gorczyca, S C Nair, B Jilma, et al.
Frontiers in Pharmacology|August 8, 2022
Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)M Karolyi, E Pawelka, S Omid, et al.
Leukemia|August 1, 2017
Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target siteE Hadzijusufovic, K Albrecht-Schgoer, K Huber, et al.
Leukemia|December 3, 2016
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinibL Kazianka, C Drucker, C Skrabs, et al.
Pageof 14